DUBLIN--(BUSINESS WIRE)--The "Global Orphan Drugs Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Orphan Drugs market is expected to reach $398.93 billion by 2026 growing at a CAGR of 13% during the forecast period.
The demand for orphan drugs has increased significantly owing to the surge in prevalence of rare diseases. However, the limited patient pool for clinical trials and product marketing is hampering the market. Moreover, growth in novel indications for known orphan drugs and untapped emerging economies are expected to provide new market opportunities to orphan drug manufacturers in the near future.
Based on the Therapy Class, the Oncology segment is estimated to have a lucrative growth due to the rise in the number of patients suffering from different types of cancers. This also increases the demand for novel therapeutics, which as per the report will bode well for the global orphan drugs market.
The key vendors mentioned are Alexion Pharmaceuticals Inc, Amgen Inc, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited, GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analyzed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Orphan Drugs Market, By Drug Type
5.1 Introduction
5.2 Biologics
5.3 Non-Biologics
6 Global Orphan Drugs Market, By Therapy Class
6.1 Introduction
6.2 Blood
6.3 Central Nervous Systems
6.4 Endocrine
6.5 Respiratory
6.6 Dermatology
6.7 Systemic Anti-Infectives
6.8 Musculoskeletal
7 Global Orphan Drugs Market, By Drug
7.1 Introduction
7.2 Adcetris
7.3 Darzalex
7.4 Imbruvica
7.5 Jakaf
7.6 Keytruda
7.7 Opdivo
7.8 Pomalyst
7.9 Revlimid
7.10 Rituxan
7.11 Soliris
7.12 Spinraza
7.13 Copaxone
7.14 Avonex
7.15 Sensipar
7.16 Hemlibra
7.17 Venclexta
7.18 Epidiolex
8 Global Orphan Drugs Market, By Disease Type
8.1 Introduction
8.2 Cardiovascular Diseases
8.3 Hematologic and Immunologic Diseases
8.4 Infectious Diseases
8.5 Metabolic Diseases
8.6 Neurologic Diseases
8.7 Oncological Diseases
8.8 Gastrointestinal
8.9 Pulmonary
9 Global Orphan Drugs Market, By Indication
9.1 Introduction
9.2 Acute Myeloid Lukemia
9.3 Cystic Fibrosis
9.4 Duchenne Muscular Dystrophy
9.5 Glioma
9.6 Graft vs Host Disease
9.7 Multiple Myeloma
9.8 Non-Hodgkin's Lymphoma
9.9 Ovarian Cancer
9.10 Pancreatic Cancer
9.11 Renal Cell Carcinoma
9.12 Other Indications
10 Global Orphan Drugs Market, By Phase
10.1 Introduction
10.2 Phase I
10.3 Phase II
10.4 Phase III
10.5 Phase IV
11 Global Orphan Drugs Market, By Distribution Channel
11.1 Introduction
11.2 Hospital Pharmacy
11.3 Online Sales
11.4 Retail Pharmacy
11.5 Specialty Pharmacies
11.6 Other Distribution Channels
12 Global Orphan Drugs Market, By Geography
12.1 North America
12.2 Europe
12.3 Asia Pacific
12.4 South America
12.5 Middle East & Africa
13 Strategic Benchmarking
14 Vendors Landscape
14.1 Alexion Pharmaceuticals Inc.
14.2 Amgen Inc.
14.3 AstraZeneca PLC
14.4 Bayer AG
14.5 Bristol-Myers Squibb Company
14.6 Celgene Corporation
14.7 Daiichi Sankyo Company Limited
14.8 GlaxoSmithKline PLC
14.9 Hoffmann-La Roche Ltd.
14.10 Merck & Co. Inc.
14.11 Novartis AG
14.12 Novo Nordisk A/S
14.13 Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/3bfbkm
